Cargando…
An Integrated Analysis of Network Pharmacology, Molecular Docking, and Experiment Validation to Explore the New Candidate Active Component and Mechanism of Cuscutae Semen-Mori Fructus Coupled-Herbs in Treating Oligoasthenozoospermia
PURPOSE: One of the most common types of male infertility is recognized as oligoasthenozoospermia (OA), characterized by low sperm count and quality in males. As a traditional Chinese medicine (TCM), Cuscutae Semen-Mori Fructus coupled-herbs (CSMFCH) has been known to act a curative effect on OA for...
Autores principales: | Bai, Xue, Tang, Yibo, Li, Qiang, Liu, Dan, Liu, Guimin, Fan, Xiaolei, Liu, Zhejun, Yu, Shujun, Tang, Tian, Wang, Shuyan, Li, Lingru, Zhou, Kailin, Zheng, Yanfei, Liu, Zhenquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139735/ https://www.ncbi.nlm.nih.gov/pubmed/34040346 http://dx.doi.org/10.2147/DDDT.S307015 |
Ejemplares similares
-
Network pharmacology integrated molecular docking reveals the bioactive components and potential targets of Morinda officinalis–Lycium barbarum coupled-herbs against oligoasthenozoospermia
por: Bai, Xue, et al.
Publicado: (2021) -
Medicinal herbs Fructus corni and Semen cuscutae suppress allograft rejection via distinct immune mechanisms
por: Liu, Xusheng, et al.
Publicado: (2016) -
An integrative approach to uncover the components, mechanisms, and functions of traditional Chinese medicine prescriptions on male infertility
por: Bai, Xue, et al.
Publicado: (2022) -
Assessing the Mechanism of Action of “Fructus Ligustri Lucidi-Cuscutae Semen” in Prostate Cancer Treatment Using Network Pharmacology and Molecular Docking
por: Lu, Dongdong, et al.
Publicado: (2022) -
Hua-Tan-Sheng-Jing Decoction Treats Obesity With Oligoasthenozoospermia by Up-Regulating the PI3K-AKT and Down-Regulating the JNK MAPK Signaling Pathways: At the Crossroad of Obesity and Oligoasthenozoospermia
por: Dong, Yang, et al.
Publicado: (2022)